Search Results

Harrington Discovery Institute Center for Brain Health Medicines at University Hospitals and the Alzheimer’s Drug Discovery Foundation announce a joint request for proposals for the 2024 ADDF-Harrington Scholar Award.

Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics and others are targeting the often-fatal brain tumor.

The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene therapy Kebilidi for AADC deficiency. It is the first approved gene therapy to be delivered directly to the brain.

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval in Hong Kong by the Hong Kong Patent Office

Brain Cancer Canada is excited to announce the issuance of an $80,000 grant to support groundbreaking research by Dr. Sujoy Banik and his team at Lawson Health Research Institute in London, Ontario, Canada.

New research by scientists at the Allen Institute’s Brain and Consciousness group and Cedars-Sinai offers an unprecedented look at how neurons respond to ES.

Not everything in the brain is meant to last. As our brains assemble, trillions of neural connections have to be built or torn down at the right time and place.